Keith Bostian, Ph.D.
Former Chief Scientific Officer

As an entrepreneur-scientist, Dr. Bostian has held executive operating roles in companies financed by leading venture firms in the biotechnology arena, and has played advisory roles at the seed, pre-seed, and investment stage for numerous other organizations. Previously, he was the founder and CEO of Iconix Pharmaceuticals, Inc. a leader in the emerging filed of chemogenomics, as well as founder and COO of Microcide Pharmaceuticals, Inc., a publicly traded company with clinical and pre-clinical programs focused on infectious diseases. Dr. Bostian was also previously Executive Director of Microbiology and Molecular Genetics at Merck Research Laboratories where he was responsible for the discovery and development of new anti-microbial agents, as well as the discovery of new leads from natural products for all of Merck's worldwide drug discovery programs. He is an inventor on numerous patents in drug discovery and genomics, and has led efforts resulting in a number of clinical candidates including a first-in-class new anti-fungal antibiotic, CANCIDAS. Dr. Bostian earned his doctorate in Biochemistry from the University of London.